Full metadata record
DC FieldValueLanguage
dc.creatorGarbayo, E-
dc.creatorMonter-Menei, C.N. (C.N.)-
dc.creatorAnsorena-Artieda, E. (Eduardo)-
dc.creatorLanciego, J.L. (José Luis)-
dc.creatorAymerich-Soler, M.S. (María Soledad)-
dc.creatorBlanco-Prieto, M.J. (María José)-
dc.date.accessioned2011-11-10T13:34:41Z-
dc.date.available2011-11-10T13:34:41Z-
dc.date.issued2009-
dc.identifier.citationGarbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J Control Release 2009 Apr 17;135(2):119-126.es_ES
dc.identifier.issn0168-3659-
dc.identifier.urihttps://hdl.handle.net/10171/19580-
dc.description.abstractGlial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative effect of controlled GDNF delivery using biodegradable microspheres in an animal model with partial dopaminergic lesion. Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-induced rotational asymmetry at different times and were sacrificed two months after microsphere implantation for immunohistochemical analysis. The putative presence of serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing safety issues. The results demonstrated that GDNF-loaded microspheres, improved the rotational behavior induced by amphetamine of the GDNF-treated animals together with an increase in the density of TH positive fibers at the striatal level. The developed GDNF-loaded microparticles proved to be suitable to release biologically active GDNF over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies against GDNF demonstrating the safety of glycosylated GDNF use.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectGDNFes_ES
dc.subjectPLGA microparticleses_ES
dc.subjectTROMSes_ES
dc.subjectSerum IgG antibodies against GDNFes_ES
dc.subjectParkinson´s diseasees_ES
dc.titleEffective GDNF brain delivery using microspheres-A promising strategy for Parkinson’s diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doihttp://dx.doi.org/10.1016/j.jconrel.2008.12.010es_ES

Files in This Item:
Thumbnail
File
Garbayo et al-manuscript-Revised-JCR-08-00852R1.pdf
Description
Size
630.29 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.